India, Nov. 13 -- Allarity Therapeutics, Inc. (ALLR), a clinical-stage pharmaceutical company developing personalized cancer treatments, reported third-quarter 2026 financial results and provided full-year guidance, highlighting continued clinical development of stenoparib and progress in its CLIA-certified laboratory services business.
Third-Quarter 2026 Financial Results
Research and development (R&D) expenses increased to $4.2 million for the third quarter ended September 30, 2026, compared with $1.2 million in the prior-year period.
The increase primarily reflected a one-time charge of $3.2 million for manufacturing stenoparib active pharmaceutical ingredient (API) to support potential drug supply requirements for a Phase 3 trial.
G...